Pappas Life Science Ventures VI, LP
Late investment period: no first sale reported; age from Form D filed Mar 2022 (approximate)
- Vintage
- Unknown
- Fund size
- $250M (Form D)
- Stages
- Pre-seed, Seed, Growth
- Sectors
- Biotech, Life sciences and research tools
- Regions
- NC, Global
01 · Thesis
Pappas Capital invests in life science companies, including biotechnology, biopharmaceuticals, drug delivery and medical devices. It also funds translational life science technologies, with possible seed investments in start-ups, and backs next-generation life science companies from concept to commercialization.Inferred from the firm's website
02 · Initial check
$1.67M to $3.13M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- NA Arthur M. Pappas, Manager of the General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideThe Wake Forest Technology Development Program, also known as the Catalyst Fund, is a collaborative partnership between Wake Forest University Health Sciences and Pappas Capital. It funds translational life science technologies, with the possibility of seed investments in start-ups.
The Catalyst Fund was launched with a $15 million commitment to support 25 to 30 novel technologies over a four- to five-year period.
https://www.pappas-capital.com/wake-forest-innovation-catalyst-fund/Firm-widePappas Capital invests exclusively in the life science sector, including biotechnology, biopharmaceuticals, drug delivery and medical devices.
Pappas Capital invests exclusively in the life science sector
https://www.pappas-capital.com/for-entrepreneurs/
06 · Sources
Last verified: Oct 28, 2026